MBrace Therapeutics

About MBrace Therapeutics

MBrace Therapeutics is a clinical-stage company focused on translating innovative ADC (Antibody Drug Conjugate) discovery into transformative therapies for cancer patients. The company identifies new cancer targets and develops first-in-class ADC therapeutics using proprietary technologies to address unmet needs in cancer treatment.

Products & Services

MBRC-101:A lead ADC product currently in clinical trials, targeting a novel cancer antigen.

ADC Pipeline:Multiple ADC products in development, each targeting novel antigens for cancer treatment.

Discovery Platform:Proprietary SPARTA technology for in vivo target discovery, enabling the development of cancer-specific ADC therapeutics.

Specialties

Antibody Drug Conjugates (ADC) Cancer Therapeutics Target Discovery Clinical Trials Innovative Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 85000000 MR: - FA: $85 million FAN: 85000000	D: 2023-11-14 FD: 2023-11-14	5 investors

Series B Latest

2023-11-14

$85.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jay Stamatis

Chief Executive Officer

I

Isan Chen

Co-founder, President and Chief Executive Officer

S

Steve Alley

Chief Scientific Officer

Y

Yongjian Wu

Chief Development Officer & Head of CMC

R

Reena Desai

Chief Legal Officer and Corporate Secretary

A

Allen Albright

Senior VP, Regulatory Affairs

View 13 more team members with Pro

Unlock Full Team Directory

Recent News